Quantbot Technologies’s Denali Therapeutics DNLI Stock Holding History

Quantbot Technologies’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-512	Closed	-$9.83K	–	1987
2026 Q1	$9.83K	Buy	+512	New	+$10.2K	﹤0.01%	1538
2022 Q4	–	Sell	-3,700	Closed	-$113K	–	1762
2022 Q3	$113K	Buy	3,700 +2,900	+363%	+$94.3K	0.01%	1062
2022 Q2	$23K	Buy	800 +633	+379%	+$16.6K	﹤0.01%	1431
2022 Q1	$5K	Sell	167 -3,575	-96%	-$123K	﹤0.01%	1524
2021 Q4	$166K	Buy	3,742 +3,311	+768%	+$157K	0.01%	765
2021 Q3	$21K	Sell	431 -875	-67%	-$49.3K	﹤0.01%	1258
2021 Q2	$102K	Sell	1,306 -5,823	-82%	-$360K	0.01%	906
2021 Q1	$407K	Buy	+7,129	New	+$477K	0.04%	543
2020 Q4	–	Sell	-2,981	Closed	-$106K	–	1377
2020 Q3	$106K	Buy	+2,981	New	+$89.8K	0.01%	712
2020 Q1	–	Sell	-4,477	Closed	-$77K	–	1017
2019 Q4	$77K	Buy	+4,477	New	+$74.5K	0.01%	873

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quantbot Technologies's DNLI Position: Q2 2026 in Review

Quantbot Technologies sold out of Denali Therapeutics (DNLI) in Q2 2026, closing a stake of 512 shares — an estimated $9.83K sold.

Quantbot Technologies first reported a position in DNLI in Q4 2019 and held it in 10 quarters. The position peaked at $407K in Q1 2021. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Quantbot Technologies reported no remaining Denali Therapeutics position as of Q2 2026 after selling out during the quarter.
Quantbot Technologies sold 512 Denali Therapeutics shares in Q2 2026, an estimated $9.83K.
Quantbot Technologies first reported a position in Denali Therapeutics in Q4 2019 and held it in 10 quarters.
Quantbot Technologies's Denali Therapeutics position peaked at $407K in Q1 2021.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Quantbot Technologies's 13F filing for Q2 2026, filed 12 Aug 2026.